| 1 | Natural Killer Cell–Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia | 3.1 | 2 | Citations (PDF) |
| 2 | Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma | 53.1 | 111 | Citations (PDF) |
| 3 | Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial | 22.8 | 115 | Citations (PDF) |
| 4 | CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool | 6.8 | 39 | Citations (PDF) |
| 5 | IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity | 6.8 | 70 | Citations (PDF) |
| 6 | Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening | 20.2 | 44 | Citations (PDF) |
| 7 | DNA damage induces p53-independent apoptosis through ribosome stalling | 26.5 | 150 | Citations (PDF) |
| 8 | Gene and protein sequence features augment HLA class I ligand predictions | 4.4 | 4 | Citations (PDF) |
| 9 | ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo | 0.8 | 2 | Citations (PDF) |
| 10 | Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial | 22.8 | 122 | Citations (PDF) |
| 11 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial | 22.8 | 75 | Citations (PDF) |
| 12 | Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens | 20.2 | 44 | Citations (PDF) |
| 13 | γδ T cells are effectors of immunotherapy in cancers with HLA class I defects | 31.3 | 298 | Citations (PDF) |
| 14 | PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial | 15.0 | 41 | Citations (PDF) |
| 15 | DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age | 11.0 | 27 | Citations (PDF) |
| 16 | Protocol for ex vivo culture of patient-derived tumor fragments | 0.8 | 29 | Citations (PDF) |
| 17 | Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment | 6.8 | 45 | Citations (PDF) |
| 18 | Safety switches for adoptive cell therapy | 3.7 | 50 | Citations (PDF) |
| 19 | Tertiary lymphoid structures in cancer | 26.5 | 1,090 | Citations (PDF) |
| 20 | QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment | 3.3 | 20 | Citations (PDF) |
| 21 | Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool | 14.4 | 49 | Citations (PDF) |
| 22 | PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC | 4.5 | 41 | Citations (PDF) |
| 23 | When Cancer Cells Become the Enablers of an Antitumor Immune Response | 6.8 | 12 | Citations (PDF) |
| 24 | Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma | 22.8 | 320 | Citations (PDF) |
| 25 | Formation of Tissue-Resident CD8+ T-Cell Memory | 4.6 | 31 | Citations (PDF) |
| 26 | Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines | 3.7 | 55 | Citations (PDF) |
| 27 | Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy | 6.8 | 190 | Citations (PDF) |
| 28 | Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features | 11.0 | 119 | Citations (PDF) |
| 29 | An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer | 22.8 | 363 | Citations (PDF) |
| 30 | HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial 2021, 9, e002547 | | 15 | Citations (PDF) |
| 31 | The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues | 30.1 | 208 | Citations (PDF) |
| 32 | Single-cell analysis of regions of interest (SCARI) using a photosensitive tag | 9.5 | 19 | Citations (PDF) |
| 33 | Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains | 2.3 | 3 | Citations (PDF) |
| 34 | Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response | 5.3 | 39 | Citations (PDF) |
| 35 | Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells | 4.4 | 79 | Citations (PDF) |
| 36 | Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma | 11.0 | 307 | Citations (PDF) |
| 37 | T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes | 20.2 | 36 | Citations (PDF) |
| 38 | Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial | 22.8 | 398 | Citations (PDF) |
| 39 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionCell, 2020, 183, 818-834.e13 | 23.8 | 533 | Citations (PDF) |
| 40 | Comprehensive analysis of cutaneous and uveal melanoma liver metastases 2020, 8, e001501 | | 64 | Citations (PDF) |
| 41 | Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up 2020, 8, e000848 | | 168 | Citations (PDF) |
| 42 | A committed tissue-resident memory T cell precursor within the circulating CD8+ effector T cell pool | 5.9 | 111 | Citations (PDF) |
| 43 | A mouse model that is immunologically tolerant to reporter and modifier proteins | 3.1 | 20 | Citations (PDF) |
| 44 | CD29 identifies IFN-γ–producing human CD8
+
T cells with an increased cytotoxic potential | 5.3 | 123 | Citations (PDF) |
| 45 | Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ | 15.0 | 146 | Citations (PDF) |
| 46 | Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics | 16.6 | 71 | Citations (PDF) |
| 47 | B cells and tertiary lymphoid structures promote immunotherapy response | 31.3 | 2,519 | Citations (PDF) |
| 48 | Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers | 22.8 | 1,315 | Citations (PDF) |
| 49 | Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells | 3.1 | 18 | Citations (PDF) |
| 50 | The CD47-SIRPα Immune Checkpoint | 16.6 | 690 | Citations (PDF) |
| 51 | CD8+ T cell states in human cancer: insights from single-cell analysis | 33.8 | 1,361 | Citations (PDF) |
| 52 | Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdCell, 2019, 178, 585-599.e15 | 23.8 | 244 | Citations (PDF) |
| 53 | Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis | 31.3 | 475 | Citations (PDF) |
| 54 | Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection | 11.0 | 35 | Citations (PDF) |
| 55 | Defining ‘T cell exhaustion’ | 30.1 | 1,560 | Citations (PDF) |
| 56 | Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial | 14.5 | 503 | Citations (PDF) |
| 57 | Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial | 22.8 | 854 | Citations (PDF) |
| 58 | Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy | 22.8 | 238 | Citations (PDF) |
| 59 | Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity | 3.1 | 62 | Citations (PDF) |
| 60 | SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing | 1.5 | 46 | Citations (PDF) |
| 61 | Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer | 11.0 | 144 | Citations (PDF) |
| 62 | Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaCell, 2019, 176, 775-789.e18 | 23.8 | 1,091 | Citations (PDF) |
| 63 | Cancer Neoantigens | 22.4 | 556 | Citations (PDF) |
| 64 | T Cell Dysfunction in Cancer | 28.7 | 1,219 | Citations (PDF) |
| 65 | Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating LymphocytesCell, 2018, 172, 549-563.e16 | 23.8 | 282 | Citations (PDF) |
| 66 | Regulation and Function of the PD-L1 Checkpoint | 16.6 | 2,060 | Citations (PDF) |
| 67 | T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide–MHC complexes | 20.2 | 103 | Citations (PDF) |
| 68 | Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma | 22.8 | 823 | Citations (PDF) |
| 69 | Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018, 174, 1586-1598.e12 | 23.8 | 1,087 | Citations (PDF) |
| 70 | A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade | 22.8 | 1,119 | Citations (PDF) |
| 71 | Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers | 22.8 | 565 | Citations (PDF) |
| 72 | Abstract B54: Dissecting immune cell heterogeneity in human cancer by single-cell RNA-sequencing 2018, , | | 0 | Citations (PDF) |
| 73 | HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia | 3.2 | 20 | Citations (PDF) |
| 74 | Guidelines for the use of flow cytometry and cell sorting in immunological studies
* | 2.4 | 589 | Citations (PDF) |
| 75 | Antigen receptor repertoire profiling from RNA-seq data | 20.2 | 337 | Citations (PDF) |
| 76 | Identification of CMTM6 and CMTM4 as PD-L1 protein regulators | 31.3 | 667 | Citations (PDF) |
| 77 | T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors | 4.2 | 32 | Citations (PDF) |
| 78 | Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer | 1.1 | 15 | Citations (PDF) |
| 79 | BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts | 4.4 | 77 | Citations (PDF) |
| 80 | Preventing tumor escape by targeting a post-proteasomal trimming independent epitope | 5.9 | 24 | Citations (PDF) |
| 81 | Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors | 11.0 | 76 | Citations (PDF) |
| 82 | Neoantigens encoded in the cancer genome | 3.7 | 74 | Citations (PDF) |
| 83 | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | 19.4 | 3,085 | Citations (PDF) |
| 84 | Neoantigen landscape dynamics during human melanoma–T cell interactions | 31.3 | 456 | Citations (PDF) |
| 85 | T Cell Fate at the Single-Cell Level | 22.4 | 150 | Citations (PDF) |
| 86 | A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products | 3.9 | 2 | Citations (PDF) |
| 87 | Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines | 3.2 | 19 | Citations (PDF) |
| 88 | The Branching Point in Erythro-Myeloid DifferentiationCell, 2015, 163, 1655-1662 | 23.8 | 167 | Citations (PDF) |
| 89 | Assessing T lymphocyte function and differentiation by genetically encoded reporter systems | 8.4 | 21 | Citations (PDF) |
| 90 | Neoantigens in cancer immunotherapy | 26.5 | 4,634 | Citations (PDF) |
| 91 | Adoptive cellular therapy: A race to the finish line | 8.7 | 385 | Citations (PDF) |
| 92 | Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage | 0.8 | 31 | Citations (PDF) |
| 93 | Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor | 6.1 | 106 | Citations (PDF) |
| 94 | Functional heterogeneity of human memory CD4
+
T cell clones primed by pathogens or vaccines | 26.5 | 346 | Citations (PDF) |
| 95 | RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer | 6.1 | 67 | Citations (PDF) |
| 96 | Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition | 4.4 | 41 | Citations (PDF) |
| 97 | TCR repertoires of intratumoral T‐cell subsets | 6.1 | 61 | Citations (PDF) |
| 98 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | 31.3 | 1,954 | Citations (PDF) |
| 99 | Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype | 4.2 | 63 | Citations (PDF) |
| 100 | Anti–CTLA-4 therapy broadens the melanoma-reactive CD8
+
T cell response | 8.7 | 360 | Citations (PDF) |
| 101 | Towards error-free profiling of immune repertoires | 13.6 | 468 | Citations (PDF) |
| 102 | Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes | 5.3 | 42 | Citations (PDF) |
| 103 | Acquired and intrinsic resistance in cancer immunotherapy | 2.8 | 187 | Citations (PDF) |
| 104 | Cellular barcoding: A technical appraisal | 0.6 | 82 | Citations (PDF) |
| 105 | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma | 3.2 | 260 | Citations (PDF) |
| 106 | Single cell behavior in T cell differentiation | 8.4 | 28 | Citations (PDF) |
| 107 | Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: A potential role for heterologous immunity | 0.6 | 2 | Citations (PDF) |
| 108 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma | 22.8 | 666 | Citations (PDF) |
| 109 | The cancer antigenome | 5.2 | 224 | Citations (PDF) |
| 110 | Signatures of mutational processes in human cancer | 31.3 | 9,509 | Citations (PDF) |
| 111 | Transposon leads to contamination of clinical pDNA vaccine | 2.0 | 10 | Citations (PDF) |
| 112 | Development of a Hypersensitive Periodate‐Cleavable Amino Acid that is Methionine‐ and Disulfide‐Compatible and its Application in MHC Exchange Reagents for T Cell Characterisation | 1.9 | 23 | Citations (PDF) |
| 113 | Diverse and heritable lineage imprinting of early hematopoietic progenitors | 0.6 | 1 | Citations (PDF) |
| 114 | Diverse and heritable lineage imprinting of early haematopoietic progenitors | 31.3 | 388 | Citations (PDF) |
| 115 | Human cancer regression antigens | 3.7 | 40 | Citations (PDF) |
| 116 | Pairing of T‐cell receptor chains via emulsion PCR | 2.4 | 137 | Citations (PDF) |
| 117 | Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer | 0.8 | 44 | Citations (PDF) |
| 118 | Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma | 12.3 | 793 | Citations (PDF) |
| 119 | Mixed functional characteristics correlating with TCR‐ligand koff‐rate of MHC‐tetramer reactive T cells within the naive T‐cell repertoire | 2.4 | 32 | Citations (PDF) |
| 120 | Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission | 12.3 | 125 | Citations (PDF) |
| 121 | TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients | 3.3 | 189 | Citations (PDF) |
| 122 | Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma | 3.3 | 73 | Citations (PDF) |
| 123 | Dissection of T-cell Antigen Specificity in Human Melanoma | 4.2 | 155 | Citations (PDF) |
| 124 | Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expressionBlood, 2012, 119, 798-804 | 3.6 | 21 | Citations (PDF) |
| 125 | Intravital Microscopy Through an Abdominal Imaging Window Reveals a Pre-Micrometastasis Stage During Liver Metastasis | 8.7 | 198 | Citations (PDF) |
| 126 | Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes | 3.8 | 3 | Citations (PDF) |
| 127 | Tissue-resident memory CD8
+
T cells continuously patrol skin epithelia to quickly recognize local antigen | 5.3 | 273 | Citations (PDF) |
| 128 | Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses | 2.3 | 39 | Citations (PDF) |
| 129 | The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study | 3.2 | 16 | Citations (PDF) |
| 130 | Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers | 3.8 | 70 | Citations (PDF) |
| 131 | Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection | 7.4 | 36 | Citations (PDF) |
| 132 | High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations | 1.5 | 38 | Citations (PDF) |
| 133 | The descent of memory T cells | 2.6 | 37 | Citations (PDF) |
| 134 | Combination of targeted therapy and immunotherapy in melanoma | 3.2 | 42 | Citations (PDF) |
| 135 | Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7 | 2.8 | 32 | Citations (PDF) |
| 136 | T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success | 1.8 | 39 | Citations (PDF) |
| 137 | An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1 | 2.4 | 61 | Citations (PDF) |
| 138 | MHC-based detection of antigen-specific CD8+ T cell responses | 3.2 | 32 | Citations (PDF) |
| 139 | RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells | 3.2 | 52 | Citations (PDF) |
| 140 | Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity | 8.3 | 71 | Citations (PDF) |
| 141 | Technologies for MHC class I immunoproteomics | 1.9 | 14 | Citations (PDF) |
| 142 | Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant? | 3.9 | 9 | Citations (PDF) |
| 143 | Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones | 16.6 | 89 | Citations (PDF) |
| 144 | Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif | 3.6 | 25 | Citations (PDF) |
| 145 | Mapping the life histories of T cells | 30.1 | 52 | Citations (PDF) |
| 146 | One naive T cell, multiple fates in CD8+ T cell differentiation | 5.9 | 184 | Citations (PDF) |
| 147 | Microbead-Assisted Retroviral Transduction for Clinical Application | 2.3 | 5 | Citations (PDF) |
| 148 | Synthetic vehicles for DNA vaccination | 2.7 | 27 | Citations (PDF) |
| 149 | Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | 22.8 | 416 | Citations (PDF) |
| 150 | Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective | 2.3 | 80 | Citations (PDF) |
| 151 | Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers | 3.5 | 191 | Citations (PDF) |
| 152 | Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis | 5.3 | 207 | Citations (PDF) |
| 153 | Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin | 2.3 | 56 | Citations (PDF) |
| 154 | Preclinical development of T cell receptor gene therapy | 3.7 | 49 | Citations (PDF) |
| 155 | TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008 | 3.2 | 61 | Citations (PDF) |
| 156 | Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers | 13.6 | 322 | Citations (PDF) |
| 157 | Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells | 12.1 | 86 | Citations (PDF) |
| 158 | Generation of Peptide MHC Class I Monomers and Multimers Through Ligand Exchange | 2.4 | 52 | Citations (PDF) |
| 159 | Class I Major Histocompatibility Complexes Loaded by a Periodate Trigger | 12.1 | 30 | Citations (PDF) |
| 160 | UV-Induced Ligand Exchange in MHC Class I Protein Crystals | 12.1 | 41 | Citations (PDF) |
| 161 | The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase | 1.5 | 66 | Citations (PDF) |
| 162 | Immunotherapeutic Strategies: The Melanoma Example | 1.2 | 9 | Citations (PDF) |
| 163 | Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates | 2.0 | 48 | Citations (PDF) |
| 164 | GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial | 3.2 | 47 | Citations (PDF) |
| 165 | Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 | 5.3 | 172 | Citations (PDF) |
| 166 | Requirements for Effective Antitumor Responses of TCR Transduced T Cells | 0.8 | 52 | Citations (PDF) |
| 167 | Dissecting T cell lineage relationships by cellular barcoding | 5.9 | 121 | Citations (PDF) |
| 168 | T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model | 1.6 | 69 | Citations (PDF) |
| 169 | SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility AntigensBlood, 2008, 112, 814-814 | 3.6 | 5 | Citations (PDF) |
| 170 | Selecting highly affine and well-expressed TCRs for gene therapy of melanomaBlood, 2007, 110, 3564-3572 | 3.6 | 101 | Citations (PDF) |
| 171 | Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host diseaseBlood, 2007, 109, 3830-3838 | 3.6 | 11 | Citations (PDF) |
| 172 | Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue | 3.2 | 57 | Citations (PDF) |
| 173 | Targeting self-antigens through allogeneic TCR gene transferBlood, 2006, 108, 870-877 | 3.6 | 69 | Citations (PDF) |
| 174 | Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice | 1.6 | 57 | Citations (PDF) |
| 175 | CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40 | 5.9 | 43 | Citations (PDF) |
| 176 | Dissection of cytotoxic and helper T cell responses | 3.5 | 16 | Citations (PDF) |
| 177 | MHC multimer technology: current status and future prospects | 3.7 | 71 | Citations (PDF) |
| 178 | Direct Ex Vivo Detection of HLA-DR3–Restricted Cytomegalovirus- and Mycobacterium tuberculosis–Specific CD4+ T Cells | 0.5 | 16 | Citations (PDF) |
| 179 | Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation | 5.9 | 143 | Citations (PDF) |
| 180 | Generating CTL by HLA transplantBlood, 2004, 103, 4381-4382 | 3.6 | 2 | Citations (PDF) |
| 181 | Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition | 5.3 | 102 | Citations (PDF) |
| 182 | Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice | 5.3 | 161 | Citations (PDF) |
| 183 | Title is missing! | 1.6 | 56 | Citations (PDF) |
| 184 | Specificity and affinity motifs for Grb2 SH2-ligand interactions | 5.3 | 70 | Citations (PDF) |
| 185 | Adoptive transfer of T-cell immunity | 8.4 | 32 | Citations (PDF) |
| 186 | Effective Postexposure Treatment of Retrovirus-Induced Disease with Immunostimulatory DNA Containing CpG Motifs | 2.4 | 49 | Citations (PDF) |
| 187 | In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens | 22.8 | 285 | Citations (PDF) |
| 188 | T-cell-receptor gene therapy | 30.1 | 260 | Citations (PDF) |
| 189 | Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination | 1.6 | 70 | Citations (PDF) |
| 190 | CMV-specific CD8pos T lymphocyte differentiation in latent CMV infection | 0.5 | 4 | Citations (PDF) |
| 191 | Differentiation of CMV-specific CD8POS T lymphocytes in primary CMV infection after renal transplantation | 0.5 | 2 | Citations (PDF) |
| 192 | Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis | 5.9 | 199 | Citations (PDF) |
| 193 | Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers | 3.6 | 194 | Citations (PDF) |
| 194 | Circumventing T-cell Tolerance to Tumour Antigens | 1.3 | 7 | Citations (PDF) |
| 195 | Immunotherapy through TCR gene transfer | 14.4 | 275 | Citations (PDF) |
| 196 | Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses | 5.9 | 978 | Citations (PDF) |
| 197 | Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands | 0.8 | 40 | Citations (PDF) |
| 198 | Tracing and characterization of the low-avidity self-specific T cell repertoire | 2.4 | 58 | Citations (PDF) |
| 199 | CD27 is required for generation and long-term maintenance of T cell immunity | 14.4 | 749 | Citations (PDF) |
| 200 | Changing T cell specificity by retroviral T cell receptor display | 5.3 | 89 | Citations (PDF) |
| 201 | Junctional Biases in the Naive TCR Repertoire Control the CTL Response to an Immunodominant Determinant of HSV-1 | 16.6 | 49 | Citations (PDF) |
| 202 | Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants | 5.9 | 110 | Citations (PDF) |
| 203 | CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy | 22.8 | 458 | Citations (PDF) |
| 204 | Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells | 1.5 | 66 | Citations (PDF) |
| 205 | Systemic T cell expansion during localized viral infection | 2.4 | 78 | Citations (PDF) |
| 206 | Bioactive and nuclease-resistant L-DNA ligand of vasopressin | 5.3 | 217 | Citations (PDF) |
| 207 | In Vitro Radiolabeling of Peptides and Proteins | 3.3 | 12 | Citations (PDF) |
| 208 | Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. | 5.9 | 216 | Citations (PDF) |
| 209 | Are MHC-bound peptides a nuisance for positive selection? | 16.6 | 62 | Citations (PDF) |
| 210 | Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides. | 5.3 | 44 | Citations (PDF) |
| 211 | A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire indistinguishable from that of cell-surface-associated Kd | 2.4 | 22 | Citations (PDF) |
| 212 | Repertoire-Determining Role of Peptide in the Positive Selection of CD8+ T cells | 6.1 | 8 | Citations (PDF) |
| 213 | TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective | 23.8 | 364 | Citations (PDF) |
| 214 | Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymusCell, 1993, 73, 1041-1049 | 23.8 | 265 | Citations (PDF) |
| 215 | Incorrect attribution of peptide source | 23.8 | 0 | Citations (PDF) |
| 216 | Polymorphisms in pockets of major histocompatibility complex class I molecules influence peptide preference. | 5.9 | 39 | Citations (PDF) |
| 217 | Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules | 2.4 | 36 | Citations (PDF) |
| 218 | Preferred size of peptides that bind to H-2 Kb is sequence dependent | 2.4 | 44 | Citations (PDF) |
| 219 | A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product | 2.4 | 39 | Citations (PDF) |
| 220 | Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses | 2.4 | 51 | Citations (PDF) |
| 221 | Assembly and intracellular transport of major histocompatibility complex molecules | 3.7 | 36 | Citations (PDF) |
| 222 | Peptide selection by MHC class I molecules | 31.3 | 261 | Citations (PDF) |
| 223 | Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses | 2.4 | 97 | Citations (PDF) |
| 224 | Empty MHC class I molecules come out in the cold | 31.3 | 932 | Citations (PDF) |
| 225 | Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro | 23.8 | 430 | Citations (PDF) |
| 226 | Regulatory role of CD19 molecules in B-cell activation and differentiation | 1.5 | 60 | Citations (PDF) |
| 227 | The Human Cell Atlas | 1.0 | 2,374 | Citations (PDF) |
| 228 | Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients | 1.0 | 69 | Citations (PDF) |
| 229 | Clinical development of cancer vaccines | 22.8 | 11 | Citations (PDF) |
| 230 | Social status impacts T-cell responses through synapse strength in the prefrontal cortex | 10.2 | 0 | Citations (PDF) |
